Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.
Bianca Weinstock-GuttmanJesper HagemeierKatelyn S KavakVasu SainiKara PatrickDeepa P RamasamyMuhammad NadeemEllen CarlDavid HojnackiRobert ZivadinovPublished in: Journal of neurology, neurosurgery, and psychiatry (2016)
Natalizumab discontinuation therapy was associated with development of new disease activity. Our tapered protocol showed benefits, as patients in the TG experienced less relapses and lower accumulation of MRI lesions compared to those in the IDG.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- randomized controlled trial
- chronic kidney disease
- rheumatoid arthritis patients
- clinical trial
- newly diagnosed
- ankylosing spondylitis
- magnetic resonance imaging
- prognostic factors
- open label
- peritoneal dialysis
- juvenile idiopathic arthritis
- study protocol
- computed tomography
- mesenchymal stem cells
- magnetic resonance
- smoking cessation